MDT-AP-0363
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 24
- os_event
- false
- age_years
- 9
- sex
- F
- new_clusters
- C4
- umap1_2d
- 3.843450974
- umap2_2d
- 3.660424003
- umap1_3d
- 1.014465585
- umap2_3d
- -1.407535765
- umap3_3d
- -2.554124547
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
- ALLOGRAFT_REJECTION+0.550
- INTERFERON_ALPHA_RESPONSE+0.540
- COAGULATION+0.510
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- INFLAMMATORY_RESPONSE+0.480
- TNFA_SIGNALING_VIA_NFKB+0.480
- ANGIOGENESIS+0.440
- COMPLEMENT+0.430
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- MYC_TARGETS_V1-0.380
- OXIDATIVE_PHOSPHORYLATION-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.290
- DNA_REPAIR-0.260
- PROTEIN_SECRETION-0.250
- MITOTIC_SPINDLE-0.240
- PANCREAS_BETA_CELLS-0.190
- ADIPOGENESIS-0.170
- WNT_BETA_CATENIN_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3331 | Med | Medulloblastoma | 0.939 |
| 2 | MDT-AP-2869 | Med | Medulloblastoma | 0.932 |
| 3 | MNG663 | — | — | 0.920 |
| 4 | MDT-AP-2936 | Med | Medulloblastoma | 0.919 |
| 5 | BS_4EN8D8Y4 | low-grade glioma | — | 0.916 |
| 6 | BS_YY5B2XDD | pilocytic astrocytoma | — | 0.916 |
| 7 | SRR1469495 | GTEX | — | 0.915 |
| 8 | MDT-AP-1168 | Med | Medulloblastoma | 0.913 |
| 9 | MDT-AP-3277 | Med | Medulloblastoma | 0.913 |
| 10 | BS_RGPSEMHC | Posterior Fossa Ependymoma | — | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| COAGULATION | 0.510 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |